FOXO1 and breast carcinoma: Inhibition of FOXO1 through drugs like AS1842856 and trifluoperazine has shown promise in reducing blood sugar [75], impairing autophagy in diabetes [76], preventing left ventricular atrophy [77], and overcoming chemoresistance in breast cancer [78].